SCHEMBL485265

SCHEMBL485265

COc1ccc(F)c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.57
EP300 Q09472 1/20 0.55
KAT8 Q9H7Z6 1/20 0.55
IMPDH2 P12268 1/20 0.52
IMPDH1 P20839 1/20 0.52
NQO1 P15559 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
MAPT P10636 3/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA4 P22748 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
PLK1 P53350 1/20 0.46
HPGDS O60760 1/20 0.44
CDC25B P30305 1/20 0.43
FABP4 P15090 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL485409 0.86 BCHE (0.47) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL419307 0.85 IDO1 (0.73) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL29380721 0.85 IDO1 (0.73) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL7753164 0.78 IDO1 (0.64) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL12019777 0.78 IDO1 (0.64) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL12019841 0.78 IDO1 (0.64) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL31666411 0.78 IDO1 (0.64) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL485292 0.78 GPR84 (0.44) IDO1EP300KAT8IMPDH2IMPDH1
SCHEMBL30366540 0.77 HPRT1 (0.46) IDO1MAPTNFE2L2KDM4EALDH1A1
SCHEMBL6562728 0.77 HPRT1 (0.46) IDO1MAPTNFE2L2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105164148-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2015-12-16 CN claimed
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases BEIGENE, LTD. (KY) 2021-01-05 US disclosed
CN-105164148-A Hepatitis c virus inhibitors BRISTOL MYERS SQUIBB CO 2015-12-16 CN disclosed
EP-2040690-B1 INHIBITORS OF CXCR2 SANOFI SA (FR) 2014-08-06 EP disclosed
US-8552033-B2 Inhibitors of CXCR2 SANOFI (FR) 2013-10-08 US disclosed
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 US disclosed
US-8283479-B2 CXCR2 inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-10-09 US disclosed
EP-1836158-B1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI AVENTIS DEUTSCHLAND (DE) 2012-02-01 EP disclosed
US-20110184177-A1 CXCR2 INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-07-28 US disclosed
US-7919628-B2 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-04-05 US disclosed
CN-101094830-A Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation SANOFI AVENTIS DEUTSCHLAND (DE) 2007-12-26 CN disclosed
EP-1836158-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION Sanofi-Aventis Deutschland GmbH (DE) 2007-09-26 EP disclosed
WO-2006069656-A1 FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-07-06 WO disclosed
EP-0109311-B1 N,N-DIALKYL-2-(4'-SUBSTITUTED-1'-NAPHTHOXY)PROPIONAMIDES STAUFFER CHEMICAL COMPANY (US) 1987-07-01 EP disclosed
EP-0109311-A1 N,N-dialkyl-2-(4'-substituted-1'-naphthoxy)propionamides STAUFFER CHEMICAL COMPANY (US) 1984-05-23 EP disclosed
US-4298532-A INTERMEDIATES FOR MICROBIOCIDES RIKER LABORATORIES, INC. (US) 1981-11-03 US disclosed
US-4260547-A MICROBIOCIDES RIKER LABORATORIES, INC. (US) 1981-04-07 US disclosed
US-4231965-A CHEMICAL INTERMEDIATES FOR MICROBIOCIDES RIKER LABORATORIES, INC. (US) 1980-11-04 US disclosed
US-4154848-A MICROBIOCIDES, BACTERICIDES RIKER LABORATORIES, INC. (US) 1979-05-15 US disclosed
US-4128659-A 2-NITRO-3-PHENYL-BENZOFURANS RIKER LABORATORIES, INC. (US) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10882856-B2 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases IDO1, TPH1, IDO2 IDO1 1/4885EP300 3616/4885KAT8 1809/4885
US-20110184177-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR4 IDO1 1811/4885EP300 3523/4885KAT8 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.